Going FurTher (Social)

Role: Copywriter

For patients with breast cancer, answers today can lead to more hope for tomorrow. Yet many diagnostic tests fall short—especially when it comes to detecting low HER2 expression, an early and critical indicator of disease progression.

Roche Diagnostics set out to change that with an advanced companion test designed to identify lower levels of HER2 expression. Now, physicians can uncover new possibilities for treatment earlier, offering renewed hope and a clearer path forward for patients.